StreetInsider.com News Articles

Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski

Thu, 10 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260910/27045461.html

NEJM publishes Takeda's phase 3 data on narcolepsy drug oveporexton

Wed, 09 Sep 2026 08:24:29 -0400

Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) announced that the New England Journal of Medicine has published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 agonist, in adults with narcolepsy type 1 (NT1).

The FirstLight study enrolled 168 participants randomized to twice-daily doses of 2mg, 1mg, or placebo. The RadiantLight study enrolled 105 participants randomized to twice-daily 2mg or placebo. Both studies ran for 12 weeks and assessed 14 primary and secondary endpoints.

Both studies showed statistically significant improvements compared to placebo in wakefulness, sleepiness, cataplexy, disease severity, and quality of life measures, with p-values below

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

Wed, 09 Sep 2026 08:24:00 -0400

Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms
Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies
Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

Wed, 09 Sep 2026 08:24:00 -0400

Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms
Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies
Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway

Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,300 at Morgan Stanley

Fri, 04 Sep 2026 06:59:56 -0400

Morgan Stanley analyst Shinichiro Muraoka lowered the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,300.00 (from JPY7,000.00) while maintaining a Overweight rating.

Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,300 at Morgan Stanley

Fri, 04 Sep 2026 06:59:56 -0400

Morgan Stanley analyst Shinichiro Muraoka lowered the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,300.00 (from JPY7,000.00) while maintaining a Overweight rating.

Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,300 at Morgan Stanley

Fri, 04 Sep 2026 06:59:56 -0400

Morgan Stanley analyst Shinichiro Muraoka lowered the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,300.00 (from JPY7,000.00) while maintaining a Overweight rating.

Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,300 at Morgan Stanley

Fri, 04 Sep 2026 06:59:56 -0400

Morgan Stanley analyst Shinichiro Muraoka lowered the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,300.00 (from JPY7,000.00) while maintaining a Overweight rating.

Form 4 TAKEDA PHARMACEUTICAL For: Sep 02 Filed by: Plump Andrew Stewart

Thu, 03 Sep 2026 21:49:00 -0400

si-local-file:///var/storage/secattach/20260903/27026644.html

Form 144 TAKEDA PHARMACEUTICAL Filed by: Plump Andrew Stewart

Wed, 02 Sep 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260902/27019171.html

Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,700 at Nomura/Instinet

Wed, 02 Sep 2026 08:12:50 -0400

Nomura/Instinet analyst Hiroyuki Matsubara raised the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,700.00 (from JPY6,500.00) while maintaining a Buy rating.

Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,700 at Nomura/Instinet

Wed, 02 Sep 2026 08:12:50 -0400

Nomura/Instinet analyst Hiroyuki Matsubara raised the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,700.00 (from JPY6,500.00) while maintaining a Buy rating.

Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,700 at Nomura/Instinet

Wed, 02 Sep 2026 08:12:50 -0400

Nomura/Instinet analyst Hiroyuki Matsubara raised the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,700.00 (from JPY6,500.00) while maintaining a Buy rating.

Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,700 at Nomura/Instinet

Wed, 02 Sep 2026 08:12:50 -0400

Nomura/Instinet analyst Hiroyuki Matsubara raised the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,700.00 (from JPY6,500.00) while maintaining a Buy rating.

Form 6-K TAKEDA PHARMACEUTICAL For: Aug 28

Mon, 31 Aug 2026 06:58:00 -0400

si-local-file:///var/storage/secattach/20260831/27000687.html

FDA approves Takeda's Mimrylo for rare blood cancer polycythemia vera